Polycystic ovary syndrome (PCOS) is a complex disorder associated with ovarian dysfunction,\ninfertility, menstrual irregularity, and hormonal impairments. Over the last decade, several studies have\nshown that some PCOS women have insulin resistance (InsR) and hyperinsulinemia, apart from being\noverweight or obese. Therefore, a crucial clinical aspect is that PCOS patients might develop glucose\nintolerance and type 2 diabetes. Insulin-sensitizing drugs have been used as first-line treatment to\nimprove hyperinsulinemia inwomen with PCOS. Although reducing PCOS symptoms and signs, several\nused insulin-sensitizer drugs may induce side effects, which reduces compliance. D-chiro-inositol (DCI),\nwhich is a naturally occurring stereoisomer of inositol, has been classified as an insulin-sensitizer and\nseems to mitigate multiple InsR-related metabolic alterations in PCOS with a safe profile. However,\naccording to a multi-targeted design, the supplementation with DCI can be synergistically integrated\nby combining other potential insulin-sensitizing drugs and/or nutraceuticals. The literature provides\nthe initial support for using several unexplored nutraceutical interventions that may target relevant\nmetabolic abnormalities associated with InsR in PCOS. With a need to promote interest in clinical\nresearch, this review aims to discuss the efficacy of DCI and the role of emerging nutraceuticals for\nmanaging InsR in PCOS.
Loading....